Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi For The Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Following The Administration of Either Moderately or Highly Emetogenic Chemotherapy Regimens

NCT00343460 is registered in ClinicalTrials.gov with Heron Therapeutics as lead sponsor.

NCT NCT00343460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00343460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi For The Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Following The Administration of Either Moderately or Highly Emetogenic Chemotherapy Regimens
Lead sponsor
Heron Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2006
Completion date
February 28, 2009
Enrollment
1,428 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

nausea and vomiting, unspecified adult solid tumor, protocol specific